Facts about the Company
Established in 1678
The company's history began in 1678 when Tanabeya Gohei the 1st opened a store in Tosabori, Osaka producing and selling Tanabeya Infusing Medicine.
the sales revenue
379.8 billion yen
In FY2019, the sales revenue of was 379.8 billion yen and core operating profit was 190.0 billion yen. Overseas sales ratio was approximately 28%, royalty revenue accounts for a large portion of the total sales.
sales of ethical drugs 98%
98% of sales were from ethical drugs.
- Ethical drugs: Drugs prescrbed by a doctor
- OTC drugs: Drugs that do NOT require a doctor's prescription
Growth Strategy for 2030
The outline of growth strategy to achieve VISION 30 "Be a healthcare company that delivers optimal therapy to each individual." is based on precision medicine and around the pill solutions. Through these two approaches, we will collect and analyze healthcare data to continue improving the value of our therapeutics and solutions, with the goal of building up our strengths to become a recognized name in central nervous system, immuno-inflammation, and other domains.
End of FY2019
The Group has positioned its approach to diversity and inclusion as one of its management strategies. We have organized that approach into the Diversity Promotion Circle, and we are advancing initiatives on that basis for leveraging diverse human resources and maximizing results
8 material issues
We will work to address these material issues in order to realize our MISSION "Creating hope for all facing illness." and VISION 30 "Be a healthcare company that delivers optimal therapy to each individual.", as well as to advance growth strategies and create hope.
- 1Innovative pharmaceuticals and healthcare services
- 2Quality assurance and stable supply
- 3Appropriate use of products
- 4Access to healthcare
- 5Stakeholder engagement
- 6Employee health, diversity and inclusion
- 7Environment-friendly business
- 8Ethics, fairness and integrity
the first ALS
in 22 years in the U.S.
Radicava is world's first demonstration of control to slow the decline in the loss of physical function in ALS patients and as the first FDA-approved ALS treatment option in 22 years in the U.S., it
An estimated 5,000-6,000 Americans are diagnosed each year with ALS.
114th place in
Yuru-Chara Grand Prix
Tanamin, Mitsubishi Tanabe Pharma's original character, is a fairy with big blue hands covered in fluffy white fur.Tanamin makes everyone feel better with a big hugs.